Qual é o preço para Freeline Therapeutics Holdings plc (FRLN)

O preço para Freeline Therapeutics Holdings plc (FRLN) é $6.48

Qual é a capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN)

A capitalização de mercado para Freeline Therapeutics Holdings plc (FRLN) é $15.41M

Freeline Therapeutics Holdings plc (FRLN) Índice P/VPA

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Ano	Rácio P/B	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rácio P/B

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/B	Diferença do rácio P/B	País
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	3.4612	-	BE

Empresa

Rácio P/B

Diferença do rácio P/B

País